uniQure Shares Slump as AMT-130 Benefit Looks Weaker at Four Years
AMT-130 slowed Huntington’s 44% at four years, but the result lost statistical significance after stronger three-year data. Stock falls as FDA review begins.
/ 14 items
#QURE↓
William Blair Restarts uniQure Coverage at $73, Sees Path for Huntington’s Gene Therapy
William Blair restarts QURE coverage with a $73 estimate, citing a clearer FDA path for AMT-130 in Huntington’s and cash funding into 2030.
FDA Signals Accelerated Approval Path for uniQure’s Huntington’s Gene Therapy AMT-130
uniQure receives positive FDA feedback for accelerated approval of its one-time gene therapy AMT-130 for Huntington’s disease. BLA submission planned for Q3 2026.
Eye Doctor and Fox News Regular Eyed as New Head of FDA Vaccine Division
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.
Oppenheimer Sees $1 Billion Potential in Passage Bio’s PBFT02 for FTD
Oppenheimer just started coverage on Passage Bio with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026.
uniQure Stock Soars as FDA's Vinay Prasad Exit Sparks Analyst Upgrades
uniQure stock jumps after Wells Fargo ($60 PT) and RBC ($35 PT) upgrades, driven by Vinay Prasad's FDA exit boosting AMT-130 Huntington's gene therapy outlook.